Founded in 2010, Q-Line Biotech Ltd. operates in the in-vitro diagnostics (IVD) segment with activities spanning the development, manufacturing, marketing, import, and distribution of diagnostic reagents, consumables, and healthcare diagnostic equipment. The company supplies diagnostic products to hospitals, diagnostic laboratories, and medical colleges, either directly or through its distribution network. Its product portfolio includes clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and point-of-care (POC) devices along with rapid testing solutions. Over the years, the company has expanded its presence in the diagnostics sector through manufacturing operations, research and development activities, and quality control processes. According to company information, Q-Line Biotech Ltd. has been supplying diagnostic equipment and IVD products since 2013 to address varied healthcare diagnostic requirements across multiple institutions.
The company’s manufacturing operations include the production of reagents and diagnostic kits, along with the supply and manufacturing of pathology and IVD equipment. As of December 31, 2025, the company reported an annual manufacturing capacity of around 1.4 million kits across categories such as haematology, clinical chemistry, and rapid/ELISA testing, in addition to approximately 1,200 Selectra Machines. As of March 31, 2026, the manufacturing division included 126 employees and 223 third-party workers involved across research and development, supply chain functions, and production-related activities. The company states that its operations are supported by collaborations with external partners and internal teams to maintain manufacturing and operational processes within the diagnostic healthcare segment.